Vivus updates of ED drug avanafil

Vivus, a US biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes  and sexual health, has initiated an open-label safety study (TA-314)  with its investigational drug avanafil, in males with erectile  dysfunction.

The firm also said that it has completed enrollment in REVIVE (TA-301),  a randomized, double-blind, placebo-controlled Phase III study of  avanafil in men with a history of generalized ED and the first of  several planned Phase III studies of avanafil. Around 650 patients have  been enrolled in the study, top-line results of which are expected in  the fourth quarter.

Avanafil is a next-generation, fast-acting, selective, oral,  phosphodiesterase type 5 inhibitor. The Phase III program for the drug  is funded through a $30.0-million collaboration with Deerfield  Management.